Logo image of OCDX

ORTHO CLINICAL DIAGNOSTICS H (OCDX) Stock Fundamental Analysis

NASDAQ:OCDX - Nasdaq - GB00BMDNH979 - Common Stock

17.63  +0.08 (+0.46%)

Fundamental Rating

1

Taking everything into account, OCDX scores 1 out of 10 in our fundamental rating. OCDX was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of OCDX have multiple concerns. OCDX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OCDX was profitable.
OCDX Yearly Net Income VS EBIT VS OCF VS FCFOCDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 200M -200M

1.2 Ratios

Industry RankSector Rank
ROA -0.01%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OCDX Yearly ROA, ROE, ROICOCDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 10 -10 20 30

1.3 Margins

Industry RankSector Rank
OM 8.03%
PM (TTM) -0.02%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OCDX Yearly Profit, Operating, Gross MarginsOCDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 20 -20 40

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for OCDX has been increased compared to 1 year ago.
OCDX has a better debt/assets ratio than last year.
OCDX Yearly Shares OutstandingOCDX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 50M 100M 150M 200M
OCDX Yearly Total Debt VS Total AssetsOCDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of 1.00, we must say that OCDX is in the distress zone and has some risk of bankruptcy.
OCDX has a Debt/Equity ratio of 4.91. This is a high value indicating a heavy dependency on external financing.
Industry RankSector Rank
Debt/Equity 4.91
Debt/FCF N/A
Altman-Z 1
ROIC/WACCN/A
WACCN/A
OCDX Yearly LT Debt VS Equity VS FCFOCDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 0 1B -1B 2B 3B

2.3 Liquidity

OCDX has a Current Ratio of 1.89. This is a normal value and indicates that OCDX is financially healthy and should not expect problems in meeting its short term obligations.
OCDX has a Quick Ratio of 1.29. This is a normal value and indicates that OCDX is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.29
OCDX Yearly Current Assets VS Current LiabilitesOCDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.31% over the past year.
Looking at the last year, OCDX shows a quite strong growth in Revenue. The Revenue has grown by 9.17% in the last year.
Measured over the past years, OCDX shows a small growth in Revenue. The Revenue has been growing by 3.80% on average per year.
EPS 1Y (TTM)99.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%132.25%
Revenue 1Y (TTM)9.17%
Revenue growth 3Y4.55%
Revenue growth 5Y3.8%
Sales Q2Q%-1.32%

3.2 Future

The Earnings Per Share is expected to grow by 13.74% on average over the next years. This is quite good.
OCDX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.40% yearly.
EPS Next Y11.82%
EPS Next 2Y13.33%
EPS Next 3Y13.79%
EPS Next 5Y13.74%
Revenue Next Year1.8%
Revenue Next 2Y3.66%
Revenue Next 3Y4.3%
Revenue Next 5Y4.4%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
OCDX Yearly Revenue VS EstimatesOCDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B 2B 2.5B
OCDX Yearly EPS VS EstimatesOCDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 21.77, which indicates a rather expensive current valuation of OCDX.
The average S&P500 Price/Earnings ratio is at 29.62. OCDX is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 16.95, which indicates a correct valuation of OCDX.
OCDX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.70.
Industry RankSector Rank
PE 21.77
Fwd PE 16.95
OCDX Price Earnings VS Forward Price EarningsOCDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 12.6
OCDX Per share dataOCDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as OCDX's earnings are expected to grow with 13.79% in the coming years.
PEG (NY)1.84
PEG (5Y)N/A
EPS Next 2Y13.33%
EPS Next 3Y13.79%

More info and screens

0

5. Dividend

5.1 Amount

OCDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORTHO CLINICAL DIAGNOSTICS H

NASDAQ:OCDX (5/26/2022, 8:13:30 PM)

17.63

+0.08 (+0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-04 2022-05-04
Earnings (Next)08-02 2022-08-02
Inst Owners0.46%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.19B
Analysts74.55
Price Target21.74 (23.31%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 21.77
Fwd PE 16.95
P/S 2.06
P/FCF N/A
P/OCF N/A
P/B 9.45
P/tB N/A
EV/EBITDA 12.6
EPS(TTM)0.81
EY4.59%
EPS(NY)1.04
Fwd EY5.9%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.56
BVpS1.86
TBVpSN/A
PEG (NY)1.84
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.01%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 8.03%
PM (TTM) -0.02%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 4.91
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.29
Altman-Z 1
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%132.25%
EPS Next Y11.82%
EPS Next 2Y13.33%
EPS Next 3Y13.79%
EPS Next 5Y13.74%
Revenue 1Y (TTM)9.17%
Revenue growth 3Y4.55%
Revenue growth 5Y3.8%
Sales Q2Q%-1.32%
Revenue Next Year1.8%
Revenue Next 2Y3.66%
Revenue Next 3Y4.3%
Revenue Next 5Y4.4%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A